Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular...

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Therapeutic inhibition of the vascular endothelial growth factor (VEGF) signaling pathway (VSP) is a common cancer treatment strategy.
• VSP inhibitors, including monoclonal antibodies and tyrosine kinase inhibitors, are associated with cardiovascular toxicities.
• Left ventricular (LV) dysfunction is a noted cardiotoxicity linked to VSP inhibitors.

Purpose of the Study:

• To review left ventricular (LV) dysfunction associated with VEGF signaling pathway (VSP) inhibitors.
• To explore potential strategies for detecting and managing VSP inhibitor-induced cardiotoxicity.
• To identify gaps in current knowledge and suggest future research directions.

Main Methods:

• Literature review of existing studies on VSP inhibitor-associated LV dysfunction.
• Analysis of pre-clinical models to understand cardiotoxicity mechanisms.
• Discussion of clinical implications and management strategies.

Main Results:

• Data on VSP inhibitor-associated LV dysfunction are predominantly from retrospective studies.
• Pre-clinical models offer insights into the mechanisms of VSP inhibitor-induced cardiotoxicity.
• Current data specific to VSP inhibitor-associated LV dysfunction are limited.

Conclusions:

• Prospective studies are essential to establish the clinical significance of VSP inhibitor-associated LV dysfunction.
• Understanding cardiotoxicity mechanisms may aid in managing other cardiomyopathies.
• Further research is needed to refine detection and management strategies for VSP inhibitor-induced LV dysfunction.